Ceribell Q2 Revenue Beats, Guidance Raised; New Credit Facility and FDA Clearances Disclosed
CBLL sits 78% above its 52-week low of $10.85.
Summary
Ceribell posted Q2 revenue of $28.1M, beating estimates, and raised full-year guidance to $114M-$117M. The company also disclosed a new $50M credit facility, two FDA clearances, and progress in its patent infringement case against Natus.
Key Events · Earnings and Guidance · CBLL
-
Q2 Revenue Beat and Raised Guidance
Revenue of $28.1M grew 33% YoY, exceeding the $27.3M consensus. Full-year 2026 guidance raised to $114M-$117M, up from prior implied range.
-
Net Loss Widens on Higher OpEx
Net loss increased to $19.3M from $13.6M in Q2 2025, driven by a 37% rise in operating expenses, including legal costs from the Natus patent infringement suit.
-
New $50M Credit Facility
Entered into a Credit Agreement with MidCap providing a $30M term loan commitment, $25M uncommitted, and a $20M revolver (expandable to $30M). Drew $20M on the revolver to repay prior $20M term loan.
-
FDA Clearances Expand Product Pipeline
Received 510(k) clearance for EEG Artifact Reduction and Epileptiform Abnormality Detection algorithms, and for a next-generation hardware platform.
Analysis · CBLL · Industrial Applications And Services
A strong second quarter saw Ceribell deliver revenue of $28.1M, up 33% year-over-year and ahead of the $27.3M consensus. Full-year guidance was raised to $114M-$117M, signaling confidence in continued growth. However, net losses widened to $19.3M from $13.6M a year ago, driven by higher operating expenses including legal costs from the Natus patent infringement suit. The company also disclosed a new $50M credit facility with MidCap, drawing $20M on the revolver to repay its prior term loan, which strengthens liquidity but adds debt. Two new FDA 510(k) clearances and a next-gen hardware platform clearance expand the product pipeline. The Natus trial concluded, with an initial determination expected by November 19, 2026 — a key upcoming catalyst. The Delirium Monitor System received NTAP, effective October 1, 2026, which could boost hospital adoption. A $1.6M IEEPA tariff refund was recognized, with $1.0M received in cash. Overall, the quarter shows strong top-line momentum and strategic progress, but rising costs and legal overhang temper the outlook.
At the time of this filing, CBLL was trading at $19.30 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $732.3M. The 52-week trading range was $10.85 to $24.33. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.